Principle Scientist, DMPK

COMPANY OVERVIEW

AIRNA is a biotechnology company with a mission to transform lives, one RNA edit at a time.

AIRNA is pioneering the discovery and development of RNA editing therapeutics to realize the therapeutic potential of base editing for patients with rare and common diseases. RNA editing modality is poised to lead the next generation of RNA therapeutics by bringing the precision of gene editing technology with a potent and safe medicine that can be conveniently re-dosed and manufactured. Our RESTORE+™ platform is based on groundbreaking research by academic co-founders Thorsten Stafforst (University of Tübingen) and Jin Billy Li (Stanford University), who were the first to elucidate a therapeutic approach for precise editing of RNA.

AIRNA has received $90 million in Series A financing from world class venture capital firms, including Forbion and Arch Venture Partners, and is headquartered in Cambridge, MA with research operations in Tübingen, Germany.

JOB DESCRIPTION

AIRNA is seeking a dynamic and motivated scientific leader to join our Preclinical development group and lead our Pre-Clinical DMPK and modeling from discovery through early clinical development. This role will be responsible for integrating DMPK, toxicology, and preclinical pharmacology to support IND enabling studies and enable clinical dose projection. The candidate will be the subject matter expert and key contributor for both internal and external teams in AIRNAs drug development programs and part of the integrated program team. The successful candidate will apply DMPK and modeling expertise and employ cutting edge techniques to answer critical translational questions regarding dosing as well as dose duration as they relate to clinical development and toxicology of the novel RNA editing oligo-based therapeutics.

RESPONSIBILITIES

As a member of AIRNA's Preclinical team, your responsibilities will include:

- Integration of DMPK, modeling, toxicology and pharmacology findings to accelerate programs through the development process.
- In collaboration with the members of the preclinical team, lead and drive Preclinical, toxicology and DMPK strategy and represent the function to leadership teams.
- Key expert for DMPK and safety, providing specific knowledge and expertise to cross-functional project teams (including clinical, CMC and regulatory functions) communicating with clarity the predicted implications on clinical development.
- Leading, designing and analyzing *in vitro* and *in vivo* studies that provide insight into the ADME properties of oligo-based RNA editing therapeutics.

AIRNA

Principle Scientist, DMPK

- Identify, collaborate and establish suitable PK/PD modeling required to project starting and effective doses to support non-clinical and clinical development
- Serve as subject matter expert internally, with partners and CRO's
- Successfully identify and manage CROs regarding DMPK study execution and PK/PD modeling
- Apply PK/PD modeling to inform clinical dosing strategies and support Formulations.
- Act as primary author for DMPK and Toxicology sections of regulatory submission

QUALIFICATIONS

- MS with 8+ years or PhD with 6+ years of relevant experience in pharmaceutical drug discovery and development
- Degree in a relevant biomedical field
- Experience in IND enabling study design and execution.
- In-depth conceptual and technical expertise in oligo/RNA therapeutics discovery and development is preferred.
- Ability to work in a fast paced, startup environment

LOCATION

AIRNA has a hybrid work model, and the role will be based in AIRNA's corporate headquarters in Cambridge, MA ~3 days per week.

Are you interested in joining the team? Please apply by emailing careers@airna.com.